what is the difference between dulaglutide and semaglutide Comparative cardiovascular outcomes of to in patients with type 2 diabetes Dose distribution of dulaglutide and

Description

Severe Adverse Events: Severe treatment-emergent adverse events (TEAEs) occurred in 10.1% of the triplet therapy group, compared to 2% in the semaglutide-only group

we use data to drive every medical decision

Licensed clinicians review intake information externally and do not interact through live visits or real-time messaging

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained